WILMETTE, Ill., June 14, 2023 Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that. | June 14, 2023
Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort achieved stable. | June 1, 2023
Patient in 520 mg/m2 cohort, previously unresectable, experienced tumor shrinkage and had tumor resected following camsirubicin treatment 3 of 3 patients in the 520 mg/m2 cohort. | June 1, 2023
WILMETTE, Ill., March 27, 2023 Monopar Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the. | March 27, 2023